OCON Therapeutics’ Post

Martin Hall's research note on Tissue Regenix Group reviews the consistently strong sales growth which is forecast to continue ca. 20%. 2023 results represented the sixth consecutive six-month trading period that has exceeded 20% sales growth, owing to the implementation of TRX's '4S' Strategy which they have not wavered from. For the past three years, TRX's business plan to drive sales growth has revolved around 4 key pillars - Supply, Sales, Sustainability, and Scale. 2023 has seen the medical deice business deliver growth from existing US customers taking new product lines, lines extensions and geographical expansion. Read Martin's full note to learn more about the implementation of the commercial and operational strategy which will now focus on sustainability and scale - https://lnkd.in/eswAYG48 * We highlight the relevant business risks in the note. #lifescience #investing #capitalmarkets #pharmaceutical

Spinemarket's website, spine-market.com contains a searchable database of more than 31,000 issued and published US patents related to spinal implants, biologics, and enabling technologies. Patents are classified by type (i.e. Pedicle Screw, Interbody, Robotics...) and company (i.e. DePuy Synthes Spine or Medtronic patents are assigned to dozens of differently titled entities). Quote from major spinal implant manufacturer Chief Patent Counsel: "Here’s how I use your database. First, you do a great job in condensing all the issued patents and publications to a specific field, namely spinal implants/ instruments. This is extremely helpful. I look at the issued patents weekly to see what our competitors have issued primarily to determine if there could be any impact on what we may have under development. I review the publications for the same reason, but to also get a sense of what our competitors may be pursuing downstream."

🔎 Discover the Superior Riboflavin Formulation for Epi-On Corneal Cross-Linking 🔬 In a recent peer-reviewed publication (https://lnkd.in/dsTimU5P), #RitSight stands out as the only riboflavin formulation that effectively enriches the cornea, ensuring optimal results in epi-on corneal cross-linking. 🚦 The #theranostics technology integrated into the #C4VCHROMO4VIS device revealed significant variability among other currently available riboflavin formulations, none of which reached the efficacy threshold necessary to guarantee effective therapeutic outcomes in epi-on CXL. ⬆ The scientific study has demonstrated that #RitSight achieves #superior corneal stroma penetration - 2 to 4 times higher – than all other available ophthalmic formulations for epi-on CXL (0.1%, 0.1% TPGS, 0.15 HPMA, 0.25%). ✅Choose RitSight for next-level CXL precision and performance, backed by scientific evidence. #Keratoconus #CornealCrossLinking #PatientCare #RitSight #C4VCHROMO4VIS #Theranostics

ℹ️Evolution of Aesthetic Rejevunation Industry History helps us avoid past mistakes, understand the contexts, inspires innovation, and informs decision-making. By learning from history, we enhance our chances of success and create more impactful outcomes. Therefore, I tried to summerize the evolution of dermal injectables as below. AbbVie Allergan, Galderma, and Merz Aesthetics has played an important role in revolutionizing the industry. Main source: Kontis TC, Rivkin A. The history of injectable facial fillers. Facial Plast Surg. 2009 May;25(2):67-72. doi: 10.1055/s-0029-1220645. Epub 2009 May 4. PMID: 19415573. #Aesthetics, #Dermalfillers, #Botuliniumtoxin, #HA, #collagen, #CaHa, #PCL, #PLLA,…

Global Cellulite Treatment Market Size, Share & Trends Analysis Report 2023-2030 Featuring Leading Players - Merz Pharma, Hologic, Syneron Medical, Zimmer Aesthetics, Alma Lasers, Cymedics, and Nubway: DUBLIN, Jan. 10, 2024 /PRNewswire/ -- The "Cellulite Treatment Market Size, Share & Trends Analysis Report By Procedure Type (Non-invasive, Minimally Invasive, Topical), By Cellulite Type (Soft, Hard, Edematous), By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been...

Hardman & Co publication on Tissue Regenix Group (TRX): Six consecutive periods of >20% growth TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of products used in biosurgery, orthopaedics and dental markets. Investment in tissue processing, manufacturing capacity and strong commercial partners, together with its “4S” strategy, has generated six consecutive reporting periods of strong growth, with TRX turning EBITDA-positive in 2023. Further growth in 2024 will deliver a fully profitable, cash-generative, group. Cash will be re-invested to expand capacity even further through Phase 2, starting in 2025. Download the full report here: https://lnkd.in/eswAYG48 #research #investment #pharmaceutical #biotechnology #healthcare #healthcaretechnology #healthcaretech

Bioretec Ltd. has announced a significant update to its product development strategy: the acceleration of the development of the RemeOs™ Spinal Interbody Cage. This cutting-edge medical device is constructed from a multifunctional, MRI-compatible, absorbable hybrid composite based on its proprietary magnesium alloy. This strategic decision follows the Breakthrough Device designation granted by the US FDA in March 2024, which marks a crucial milestone for their journey toward market entry in the U.S. and beyond. With promising simulation results and technological proof of concept, they are excited to move forward into the subsequent phases. https://lnkd.in/dQxpuksq #Bioretec #Innovation #MedicalDevices #SpinalSurgery #BreakthroughTechnology #HealthcareInnovation #RemeOsCage #MedicalAdvancement

We’re proud to support the visionary innovators and relentless workers who propel America forward. Through patents and trademarks, the USPTO has helped support the manufacturing industry, which is granted about 66,000 utility patents annually. The industry accounted for about 13 million jobs in 2019, according to recent statistics from the Department of Labor. And it doesn’t stop there. We grant more than 9,500 utility patents and 500 design patents annually for medical-related manufacturing and pharmaceutical industries combined – with 3,200 trademark registrations annually. Those industries employ more than 600,000 workers in the United States. As we pause to pay homage to America’s earliest manufacturers, we celebrate modern manufacturers, like Patricia Bath. She’s the first Black woman to receive a medical patent for a device and technique she patented and manufactured for cataract surgery. #Inventor #CreatorsWanted #MFGDay24 #ThePowerOfYou #ProtectWhatYouLove Image: Courtesy National Inventors Hall of Fame

Patents are described in our costitution, as if the founding fathers knew that protecting intellectual property was a path to our fledgling country's economic development and empowerment of any individual, regardless or race, gender, or views on politics or religion. Patent protection is an example of equality. Facilitating the patent process is an example of equity, and I repost articles like this to facilitate #equitable #education. I hope it helps my #Linkedin connections to rise up in a corporation, dabble in #entrepreneurship, or simply try to improve the world by making an invention public domain. Patents have a few broad categories. This #USPTO article mentions utility patents, which is a way manufacturing companies can innovate and become more efficient at making products, keeping jobs close to home yet remaining competitive globally. Anyone who pays attention to details with a mindset to reduce mistakes and increase quality assurance can file a utility patent application. Design patents are usually a product - the thing being manufactured - and competitive design features can become a design patent. Some design patents are so recolutionary that they stand out, like my go-to example of Sara Blakely becoming the world's first female self-made billionaire after patenting Spanx legware. My design patents weren't lucrative like Sara's, but they added a few details to medical implants that helped our sales team reach new customers, which helped our company be acquired for $42 Million. The final big category are method patents, which tug at my heart because they are unicorns, broad patents that, unlike design patents, are rare and often stand alone. Many revolutionary medical treatments are method patents that solved big problems. Medical devices are unique in that we already know how many customers there are, and therefore we know our market size and can focus on #quality and #regulatory challenges. My go-to example is the inventor of spinal fusion cages - the method of placing something between spine discs to provide support for bone growth - who became the world's first overnight billionaire when Medtronic paid him $1.1 Billion for his patent portfolio and gained dominance in what was then a new $4 Billion industry that revolved around innovation, regulatory compliance, and #QualityAssurance Anyone with access to a computer and the internet - or with a pen, paper and a postage stamp - can file a patent. Black, white, brown, yellow, red, male, female, right, left, and all shades between; at a time when women and African Americans couldn't vote, they could still invent and be guaranteed equal rights under U.S. law. #Education leads to #equity, and a pen can be mightier than a college degree. To get started patenting, search "provisional patents" and read the USPTO website. Most importantly, begin with an end in mind, either your benefit or others, and try to enjoy the process and keep inevitable frustrations in perspective. Good luck!

In today's landscape of increasingly complex medical devices and their incorporation of thermally sensitive biomaterials, #SterilizationValidation is more crucial than ever. Learn more about alternative validation approaches and additional #sterilization validation methods for #MedicalDevices and #therapeutics: https://bit.ly/3TQ8QD0